Asian Journal of Pharmaceutical Sciences最新文献

{"title":"Progressive microneedles for targeting and intelligent drug delivery","authors":"Jiaqi Li,&nbsp;Qing Xia,&nbsp;Shuwen Ma,&nbsp;Zhi Wang,&nbsp;Teng Guo,&nbsp;Nianping Feng,&nbsp;Yongtai Zhang","doi":"10.1016/j.ajps.2025.101051","DOIUrl":"10.1016/j.ajps.2025.101051","url":null,"abstract":"<div><div>Microneedle-mediated drug delivery systems (MDDS) have experienced robust growth in recent years, with designers leveraging their creativity to apply these systems for direct drug delivery to the skin, mucous membranes, blood vessel walls and even internal organs. In order to achieve precise drug delivery, various delicately conceived drug release modes based on MDDS have been developed. Herein, to elucidate the design concepts of numerous reported MDDS, we have categorized them into two levels (Level-Ⅰ MDDS and Level-Ⅱ MDDS) depending on whether nanoscale and microscale carriers are integrated within the microneedles. In this work, the design strategies of MDDS, as well as the current status of their applications in targeted and intelligent drug delivery were reviewed, while their prospects and challenges for future industrialization and clinical applications were also discussed.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 3","pages":"Article 101051"},"PeriodicalIF":10.7,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicles as delivery vehicles and therapeutic agents for glioblastoma treatment: A systematic review of in vitro and in vivo preclinical studies","authors":"Jun Quan Ng ,&nbsp;Nabil Ajwad Abu Yazid ,&nbsp;Shing Cheng Tan ,&nbsp;Mastura Monif ,&nbsp;Tin Wui Wong ,&nbsp;Si-Yuen Lee","doi":"10.1016/j.ajps.2025.101043","DOIUrl":"10.1016/j.ajps.2025.101043","url":null,"abstract":"<div><div>Current treatments for glioblastoma face challenges such as the blood-brain barrier and lack of targeted therapy, compounded by the aggressive nature, high invasiveness, and heterogeneity of the disease. Exosomes, a subtype of extracellular vesicles are emerging as promising nanocarrier drug delivery systems to address these limitations. Exosomes released by all cell types can be easily obtained and modified as delivery vehicles or therapeutic agents. A systematic review was conducted to evaluate various methods for exosome isolation, characterization, engineering or modification, drug loading and delivery efficiency, including exosome biodistribution and treatment efficacy. A search of four databases for <em>in vitro</em> and <em>in vivo</em> studies (2000–,2023) identified 6165 records, of which 23 articles were found eligible and included for analyses. Most studies applied ultracentrifugation (UC) for exosomes isolation. Cancer cell lines being the most frequently used source of exosomes, followed by stem cells. The incubation approach was predominantly utilized to modify exosomes for drug loading. In vivo analysis showed that exosome biodistribution was primarily concentrated in the brain region, peaking in the first 6 h and remained moderately high. Compared to native exosomes and untreated control groups, utilizing modified native exosomes (cargo loaded) for treating glioblastoma disease models led to more pronounced suppression of tumor growth and proliferation, enhanced stimulation of immune response and apoptosis, effective restoration of drug chemosensitivity, increased anti-tumor effect and prolonged survival rates. Modified exosomes whether through incubation, sonication, transfection, freeze-thawing or their combination, improve targeted delivery and therapeutic efficacy against glioblastoma.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 3","pages":"Article 101043"},"PeriodicalIF":10.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functionalized chitosan as nano-delivery platform for CRISPR-Cas9 in cancer treatment","authors":"Asif Nawaz ,&nbsp;Nur Syamimi Ariffin ,&nbsp;Tin Wui Wong","doi":"10.1016/j.ajps.2025.101041","DOIUrl":"10.1016/j.ajps.2025.101041","url":null,"abstract":"<div><div>CRISPR-Cas system permanently deletes any harmful gene-of-interest to combat cancer growth. Chitosan (CS) is a potential cancer therapeutic that mediates via PI3K/Akt/mTOR, MAPK and NF-kβ signaling pathway modulation. CS and its covalent derivatives have been designed as nanocarrier of CRISPR-Cas9 alone (plasmid or ribonucleoprotein) or in combination with chemical drug for cancer treatment. The nanocarrier was functionalized with polyethylene glycol (PEG), targeting ligand, cell penetrating ligand and its inherent positive zeta potential to mitigate premature clearance and particulate aggregation, and promote cancer cell/nucleus targeting and permeabilization to enable CRISPR-Cas9 acting on the host DNA. Different physicochemical attributes are required for the CS-based nanocarrier to survive from the administration site, through the systemic circulation-extracellular matrix-mucus-mucosa axis, to the nucleus target. CRISPR-Cas9 delivery is met with heterogeneous uptake by the cancer cells. Choice of excipients such as targeting ligand and PEG may be inappropriate due to lacking overexpressed cancer receptor or availability of excessive metabolizing enzyme and immunoglobulin that defies the survival and action of these excipients rendering nanocarrier fails to reach the target site. Cancer omics analysis should be implied to select excipients which meet the pathophysiological needs, and chitosan nanocarrier with a “transformative physicochemical behavior” is essential to succeed CRISPR-Cas9 delivery.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 3","pages":"Article 101041"},"PeriodicalIF":10.7,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the brain: Harnessing endogenous cellular hitchhiking for targeting neoplastic and neuroinflammatory diseases","authors":"Suraj S. Wagh ,&nbsp;Paras Famta ,&nbsp;Saurabh Shah ,&nbsp;Ganesh Vambhurkar ,&nbsp;Giriraj Pandey ,&nbsp;Anupama Sikder ,&nbsp;Gurpreet Singh ,&nbsp;Shalini Shukla ,&nbsp;Abhishek Sharma ,&nbsp;Sajja Bhanu Prasad ,&nbsp;Akshay Shinde ,&nbsp;Rahul Kumar ,&nbsp;Nitin Pal Kalia ,&nbsp;Rajeev Singh Raghuvanshi ,&nbsp;Saurabh Srivastava","doi":"10.1016/j.ajps.2025.101040","DOIUrl":"10.1016/j.ajps.2025.101040","url":null,"abstract":"<div><div>Cellular hitchhiking is an emerging therapeutic strategy that uses an endogenous cell migration mechanism to deliver therapeutics to specific sites in the body. Owing to the low permeability and presence of the blood-brain barrier (BBB), the targeted delivery of therapeutics is limited, leading to inadequate localization in the brain. NCs fail to extravasate significantly into the tumor microenvironment (TME), demonstrating poor accumulation and tumor penetration. The novel cellular hitchhiking concept has been utilized to promote systemic half-life and therapeutic targeting. Neoplastic and neuroinflammatory diseases of the brain, including glioblastoma and neuroinflammation, face critical hurdles for efficiently delivering therapeutic entities owing to the BBB. Cellular hitchhiking can surmount these hurdles by utilizing various cell populations, such as stem cells, monocytes/macrophages, neutrophils, and platelets, as potential functional carriers to deliver the therapeutic cargo through the BBB. These carrier cells have the innate capability to traverse the BBB, transit through the brain parenchyma, and specifically reach disease sites such as inflammatory and neoplastic lesions owing to chemotactic navigation, <em>i.e.</em>, movement attributed to chemical stimuli. Chemotherapeutic drugs delivered by cellular hitchhiking to achieve tumor-specific targeting have been discussed. This article explores various cell types for hitchhiking NCs to the TME with in-depth mechanisms and characterization techniques to decipher the backpack dissociation dynamics (nanoparticle payload detachment characteristics from hitchhiked cells) and challenges toward prospective clinical translation.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 2","pages":"Article 101040"},"PeriodicalIF":10.7,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143637575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multifunctional tri-layer wound dressing containing ZNO nanoparticles and IGF-1 as an efficient biomaterial for healing of full thickness skin injuries","authors":"Azin Abedi Koupai ,&nbsp;Jaleh Varshosaz ,&nbsp;Mohamadreza Tavakoli ,&nbsp;Marjan Mirhaj ,&nbsp;Saeideh Salehi ,&nbsp;Faramarz Dobakhti","doi":"10.1016/j.ajps.2025.101039","DOIUrl":"10.1016/j.ajps.2025.101039","url":null,"abstract":"<div><div>Mimicking the hierarchical structure of the skin is one of the most important strategies in skin tissue engineering. Monolayer wound dressings are usually not able to provide several functions at the same time and cannot meet all clinical needs. In order to maximize therapeutic efficiency, herein, we fabricated a Tri-layer wound dressing, where the middle layer was fabricated via 3D-printing and composed of alginate, tragacanth and zinc oxide nanoparticles (ZnO NPs). Both upper and bottom layers were constructed using electrospinning technique; the upper layer was made of hydrophobic polycaprolactone to mimic epidermis, while the bottom layer consisted of Soluplus® and insulin-like growth factor-1 (IGF-1) to promote cell behavior. Swelling, water vapor permeability and tensile properties of the dressings were evaluated and the Tri-layer dressing exhibited impressive antibacterial activity and cell stimulation following by the release of ZnO NPs and IGF-1. Additionally, the Tri-layer dressing led to faster healing of full-thickness wound in rat model compared to monolayer and Bilayer dressings. Overall, the evidence confirmed that the Tri-layer wound dressing is extremely effective for full-thickness wound healing.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 3","pages":"Article 101039"},"PeriodicalIF":10.7,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144072737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multifunctional Prussian blue nanoparticles loading with Xuetongsu for efficient rheumatoid arthritis therapy through targeting inflammatory macrophages and osteoclasts","authors":"Yasi Deng ,&nbsp;Bin Li ,&nbsp;Hao Zheng ,&nbsp;Ling Liang ,&nbsp;Yupei Yang ,&nbsp;Shiqi Liu ,&nbsp;Mengyun Wang ,&nbsp;Caiyun Peng ,&nbsp;Bin Liu ,&nbsp;Wei Wang ,&nbsp;Huanghe Yu","doi":"10.1016/j.ajps.2025.101037","DOIUrl":"10.1016/j.ajps.2025.101037","url":null,"abstract":"<div><div>Abnormal activation of macrophages and osteoclasts (OCs) contributes significantly to rheumatoid arthritis (RA) development by secretion of numerous inflammatory factors. Notably, these cells exhibit significant upregulation of folate receptor proteins on their surfaces. Unfortunately, there is a current lack of safe and effective therapeutic drugs for RA. Xuetongsu (XTS), a triterpenoid compound extracted from <em>Kadsura heteroclita</em> Roxb Craib, has demonstrated the ability to significantly inhibit the proliferation of RA fibroblast-like synoviocytes (RAFLS). However, its clinical application is hampered by poor targeting and short half-life. To address these drawbacks, we previously developed a nano-drug system named HRPS nanoparticles (NPs), which effectively targets RAFLS and inhibits synovial hyperplasia. However, this system overlooked the essential role of OCs in RA-related bone destruction. Therefore, we designed a novel folate-modified biomimetic Prussian blue (PB)-XTS NP (FMPX NP) for the selective delivery of XTS into inflammatory macrophages and OCs. The NP exhibits an excellent photothermal effect when assisted by laser irradiation, facilitating targeted release of XTS within inflammatory macrophages and OCs. The synergistic anti-inflammatory and reactive oxygen species scavenging effects of PB NPs and XTS are mediated by the inhibition of the NF-κB signaling pathway in inflammatory macrophages and RANK/RANKL/NFATc1 signaling pathway in OCs. <em>In vivo</em> experiments showed that FMPX NPs extended the half-life of XTS by 2.32 times, decreased hind foot swelling from 12.10 ± 0.49 mm to 8.24 ± 0.09 mm in the model group, and prevented bone damage. In conclusion, this study introduces a novel dual-targeted nano-based therapy for RA joints and highlights its potential for biochemical photothermal triple therapy for RA. FMPX NPs inhibit arthritis-related inflammation and bone destruction through a dual-target strategy, providing new insights for targeted drug therapies in clinical RA treatment.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 3","pages":"Article 101037"},"PeriodicalIF":10.7,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced drug delivery platforms target cancer stem cells","authors":"MirAhmad Mazloomi ,&nbsp;Abolfazl Doustmihan ,&nbsp;Sajjad Alimohammadvand ,&nbsp;Hamed Hamishehkar ,&nbsp;Michael R. Hamblin ,&nbsp;Rana Jahanban Esfahlan","doi":"10.1016/j.ajps.2025.101036","DOIUrl":"10.1016/j.ajps.2025.101036","url":null,"abstract":"<div><div>Cancer stem cells (CSCs) are a major challenge in cancer therapy. Stem cell-like cells form a unique subpopulation within many tumors, which govern the degree of malignancy by promoting metastasis, recurrence, heterogeneity, and resistance to drug and radiation. Furthermore, these cells can persist in patients even after undergoing multiple cycles of conventional cancer therapy via dormancy, where they no longer dividing but remain active. These may cause cancer recurrence at any time, even years after a supposed cure, and remain invisible to the immune system. Targeting specific surface markers, signaling pathways and tumor microenvironment, which all have a significant effect on CSC function and maintenance, could help to eradicate CSCs and improve patient survival. Combinations of traditional therapies with nano-based drug delivery systems can efficiently target CSCs. Considering the biology and properties of CSCs, we classify recent approaches involving nanoparticle engineering, extracellular matrix modulation, cocktail strategies, multi-stage therapy, CSC defanging, Trojan horse systems, targeted therapy and organelle targeting. We highlight the most recent advances in nanocarrier design and drug delivery technologies to target CSCs, combined with conventional treatment in preclinical and clinical trials. The prospects of these approaches for CSCs elimination and recurrent cancer treatment are discussed.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 3","pages":"Article 101036"},"PeriodicalIF":10.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease","authors":"Fenfen Li ,&nbsp;Ruyan Yuan ,&nbsp;Jiamin Zhang ,&nbsp;Bing Su ,&nbsp;Xiaolong Qi","doi":"10.1016/j.ajps.2025.101025","DOIUrl":"10.1016/j.ajps.2025.101025","url":null,"abstract":"<div><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) has a high global incidence and associated with increased lipid accumulation in hepatocytes, elevated hepatic enzyme levels, liver fibrosis, and hepatic carcinoma. Despite decades of research and significant advancements, the treatment of MASLD still faces formidable challenges. Nanoprobes for diagnostics and nanomedicine for targeted drug delivery to the liver present promising options for MASLD diagnosis and treatment, enhancing both imaging contrast and bioavailability. Here, we review recent advances in nanotechnology applied to MASLD diagnosis and treatment, specifically focusing on drug delivery systems targeting hepatocytes, hepatic stellate cells, Kupffer cells, and liver sinusoidal endothelial cells. This review aims to provide an overview of nanomedicine's potential in early MASLD diagnosis and therapeutic interventions, addressing related complications.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 2","pages":"Article 101025"},"PeriodicalIF":10.7,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143643277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microalgae-carrying nanomedicine for bioadhesive drug delivery for treating chemotherapy-induced intestinal injury","authors":"Jie Chen ,&nbsp;Bing Wang ,&nbsp;Lan Shen ,&nbsp;Yongzhuo Huang","doi":"10.1016/j.ajps.2025.101024","DOIUrl":"10.1016/j.ajps.2025.101024","url":null,"abstract":"<div><div>Gastrointestinal tract toxicity represents a serious adverse effect of chemotherapy, leading to reduced quality of life and survival. For instance, irinotecan (CPT-11) usually causes severe gastrointestinal toxicity, with a lack of effective therapeutic interventions, making treatment often unsustainable. Therefore, development of an effective and safe therapy is crucial for improving chemotherapy efficacy and the patients’ quality of life. In this work, we developed a novel approach involving the helical-shaped cyanobacterium microalgae, <em>Spirulina platensis</em> (SP), to carry the bornyl acetate (BA)-loaded chitosan nanoparticles to enhance drug retention in the small intestine. We demonstrated the protection effect of BA against chemotherapy-induced intestinal injury using an epithelial cell model. In a mouse model, orally administered BA-ChNPs@SP accumulated in the small intestine and attenuated inflammation by reducing dsDNA release and oxidative stress. This was concomitant with the restoration of the intestinal barrier and modulation of the immune microenvironment. This work suggests the promise of the microalgae-carrying nanomedicine strategy for treatment of intestinal diseases, emphasizing its potential in addressing chemotherapy-induced gastrointestinal complications.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 2","pages":"Article 101024"},"PeriodicalIF":10.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implantable devices for resected glioblastoma therapy","authors":"Xiaoyu Chang ,&nbsp;Hui Guo ,&nbsp;Yunqian Li ,&nbsp;Jianxun Ding","doi":"10.1016/j.ajps.2025.101034","DOIUrl":"10.1016/j.ajps.2025.101034","url":null,"abstract":"<div><div>Glioblastoma (GBM) is a highly infiltrative brain tumor. The treatment of GBM is challenging due to the existence of blood brain barrier, its highly invasive nature, and its heterogeneity. Given the limitations of conventional therapies, this Perspective explores the development trajectory of implantable devices, highlighting the advantages of current models. With the progression in research, these implantable devices certainly hold promising potential for GBM therapy.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 2","pages":"Article 101034"},"PeriodicalIF":10.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143643278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}